Navigation Links
ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Date:9/19/2011

CAMBRIDGE, Mass., Sept. 19, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) and Aestus Therapeutics, Inc., announced today the expansion of their current research collaboration agreement to test additional small-molecule compounds for the ability to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).  The expanded scope of this collaboration is based on encouraging results from early-stage animal studies conducted in the past year under the existing collaboration.

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"This collaboration is an important example of how our Institute, built by the ALS community -, is dedicated to speeding the development of new therapies and has become the leader in preclinical validation of potential treatments for ALS.  We are encouraged by these early results and look forward to expanding our partnership with Aestus on behalf of patients today," says Steve Perrin, Ph.D., president and CEO of ALS TDI.

The original research collaboration was established between ALS TDI and Aestus in March 2010 to test a compound identified by Aestus's proprietary gene-based drug discovery platform in an animal model of ALS. Results obtained by ALS TDI using their rigorous pre-clinical drug testing process were encouraging and warranted expansion of the collaboration to test compounds with a similar mode of action.  

"We at Aestus are delighted to expand our research collaboration with ALS TDI to identify novel therapeutics for this devastating disease," says Tage Honore, Ph.D. D.Sc., CEO and founder of Aestus.  "The expansion of our research agreement with ALS TDI is based on a truly collaborative approach involving scientists at both institutions. We are particularly gratified that the encouraging results from experiments at ALS TDI have helped to furt
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
6. Genethon and Childrens Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
7. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
8. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
9. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
10. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
11. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... DIEGO , Sept. 3, 2015  StemProtein ... and a recent spinout of Stemedica Cell Technologies ... H. Silberg as CEO of StemProtein. Silberg ... for producing and preserving Stem Cell Factors (SCFs), ... seasoned professional in the pharmaceutical and biopharmaceutical industries ...
(Date:9/2/2015)... , Sept. 2, 2015 Axovant Sciences Ltd. (NYSE: ... of dementia, today announced upcoming presentations at three investor conferences: ... the Baird 2015 Healthcare Conference in New York ... Thursday, September 10 at 2:00 PM at the BioCentury NewsMakers ... Millennium Broadway Hotel & Conference Center , Thursday, September ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form of ... special anti-vascular endothelial growth factor agents given by injection into the eye. Dry ... a scientific protocol for the many millions diagnosed with it. AMD usually starts ...
(Date:9/2/2015)... Wellesley, Mass. (PRWEB) , ... September 02, 2015 ... ... that includes development of botanical and plant-derived compounds. BCC Research reveals in ... drugs past 2020 because this market defines the category and generates the most ...
Breaking Biology Technology:StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... of researchers has proposed a way to turn the material ... of electrons with a laser "on-off switch". Graphene is ... carbon atoms only one-atom thick, but 200 times stronger than ... than any other known material. It is almost completely transparent, ...
... June 17, 2011 Kendle International Inc. (Nasdaq: ... increased the consideration amount offered for its cash tender ... its $142.5 million aggregate principal amount of outstanding 3.375% ... No. US48880LAA52) (the "Notes").  The consideration for each $1,000.00 ...
... have been proposed for cell-based diagnostics and regenerative medicine ... develop into a desired cell type -- such as ... the clinical potential of these technologies. New research ... of the International Society for Stem Cell Research (ISSCR) ...
Cached Biology Technology:Graphene may gain an 'on-off switch,' adding semiconductor to long list of material's achievements 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/26/2015)... August 26, 2015 The report "Multi-Factor ... Five Factor), Application (Travel & Immigration, Government, Banking, Defense, ... Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market ... growing at a CAGR of 17.7% between 2015 and ... F igures spread through 169 P ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... presented at IAS build a compelling case for FUZEON ... the newest drugs to give patients facing resistance their ... treatment goal for all people living with HIV. , ... for all triple-class experienced patients. FUZEON combined with the ...
... A computer scientist at Washington University in St. Louis ... genome of a worm and has found 150 genes ... using the software, he and his colleagues have developed ... genes. , Michael Brent, Ph.D., Washington University professor of ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Newest HIV drugs should be used with FUZEON(R) 2Newest HIV drugs should be used with FUZEON(R) 3Program finds lost genes in nematode genome 2Program finds lost genes in nematode genome 3Candida albicans Genome Fully Annotated 2Candida albicans Genome Fully Annotated 3
... The GrabIt™ Kits are designed for ... cells using a pull-down method. Proteins that ... ® fusion proteins are copurified using ... complexes are retained on a spin filter. ...
... anti-Wilm's tumor, Polyclonal Antibody, Unconjugated ... Use at a dilution of 1/100. ... dilution. WB: Use at an assay ... kDa. Not tested in other applications. ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Biology Products: